Investors in Regeneron Pharmaceuticals May Have Leading Role in Securities Fraud Case

Potential Class Action Against Regeneron Pharmaceuticals

In a significant development for investors, those who purchased stocks from Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023, and October 30, 2024, have an important opportunity. The Rosen Law Firm, known for its stature in investor rights, has announced a reminder about the upcoming deadline of March 10, 2025, for anyone wishing to take a leading role in a securities fraud lawsuit against the pharmaceutical giant.

Who Can Join the Lawsuit?

If you've incurred losses exceeding $100,000 from your investments in Regeneron during the specified class period, you may qualify to serve as a lead plaintiff. Participating in this class action can be a straightforward process, as individuals may join without bearing the burden of out-of-pocket costs due to the contingency fee arrangement offered by the Rosen Law Firm.

How to Participate

Interested parties can easily express their intent to join the suit by visiting the Rosen Law Firm's website or contacting Phillip Kim, Esq. via phone or email. The firm has already filed the class action lawsuit, and those wishing to step up as lead plaintiffs must act before the deadline. Being a lead plaintiff means representing fellow investors and guiding the litigation process.

Importance of Selecting the Right Counsel

The Rosen Law Firm encourages investors not to rush this important decision. It's crucial to choose a law firm with proven experience and success in handling securities litigation. Many firms may lack the necessary qualifications, often acting merely as intermediaries. The Rosen Law Firm, with its impressive track record—including the highest recorded securities class action settlement against a Chinese company—seeks to provide substantial legal representation for its clients. Their reputation includes multiple accolades, such as being ranked the number one firm by ISS Securities Class Action Services for class action settlements in 2017 and consistently ranking among the top firms since 2013.

Allegations Against Regeneron

The lawsuit outlines various alleged discrepancies tied to Regeneron's pricing and disclosure practices. It claims that throughout the class period, the company made several misleading statements regarding its practices of subsidizing credit card fees associated with its product, Eylea. Here are the main allegations:
1. Regeneron supposedly paid credit card fees to distributors, which were conditional on those distributors not charging customers more when using a credit card.
2. These payments inflated Eylea's reported sales figures by enhancing the perceived price competitiveness of the medication.
3. The company reportedly failed to disclose significant financial dealings, such as price concessions, affecting the Average Sales Price (ASP) reported to federal agencies, in violation of the False Claims Act.
4. Ultimately, these misleading statements about the company's operations led to substantial financial losses when the true nature of these practices was revealed to the market.

Next Steps for Investors

For those interested in joining the class action, it’s crucial to act promptly. Detailed information can be accessed through the Rosen Law Firm’s website or by contacting them directly. Investors are reminded that until a class is certified, they are not automatically represented by counsel unless they specifically retain one. Therefore, if you want to ensure participation, it’s advisable to express interest as soon as possible.

As this legal fight progresses, affected investors should stay vigilant about their rights and the opportunities available to them in this pivotal legal landscape surrounding Regeneron Pharmaceuticals.

Follow for Updates

To receive real-time updates about the ongoing developments of this case, investors can follow the Rosen Law Firm on their social media channels, including LinkedIn, Twitter, and Facebook.

In a market as volatile as pharmaceuticals, being proactive about legal rights can make all the difference. Don’t miss your chance to potentially reclaim losses through this securities fraud class action lawsuit against Regeneron Pharmaceuticals.